The COVID-19 pandemic has forced significant changes on the pharmaceutical industry as companies scramble to protect employees, ensure business continuity and maintain patient access to med
Gene and cell therapy specialist Oxford Biomedica has signed a one-year agreement with AstraZeneca to manufacture the potential COVID-19 vaccine in development in partnership with Oxford Un
US biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and lung scarring in patients who have serious cases of COVID-19 or who h
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.